Helsinn gets rights to cancer candidate from Exelixis; ended
- Specialty Pharmaceuticals
- R+D and Marketing-Licensing
- Intra-Biotech Deal
- Includes Contract
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.